Does current evidence justify prostate cancer screening in Europe?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Frankel S et al. (2003) Screening for prostate cancer. Lancet 361: 1122–1128

  2. 2

    Stanford JL et al. (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283: 354–360

  3. 3

    The UK National Screening Committee (NSC) [http://www.nsc.nhs.uk/uk_nsc/uk_nsc_ind.htm]

  4. 4

    McGregor M et al. (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159: 1368–1372

  5. 5

    Draisma G et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868–878

  6. 6

    Gann PH et al. (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289–294

  7. 7

    Hakama M et al. (2001) Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 166: 2189–2191

  8. 8

    Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239–2246

  9. 9

    Thompson IM et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66–70

  10. 10

    Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984

  11. 11

    Oliver SE et al. (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355: 1788–1789

  12. 12

    Lu-Yao G et al. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 325: 740

Download references

Author information

Correspondence to Richard M Martin.

Ethics declarations

Competing interests

Richard M Martin and Jenny Donovan are principal investigators on a randomized controlled trial of the potential population impact of PSA testing for prostate cancer in the UK (Comparison arm for ProtecT trial, CAP), funded by Cancer Research UK/UK Department of Health, and the NHS Health Technology Assessment Programme.

Rights and permissions

Reprints and Permissions

About this article

Further reading